On April 11, 2018, Arbutus Biopharma Corporation and Roivant Sciences entered an agreement to launch Genevant Sciences, a jointly owned company focused on the discovery, development, and commercialization of RNA-based therapeutics enabled by Arbutus’ proprietary lipid nanoparticle (LNP) technologies.

Under the terms of the agreement, Arbutus will license exclusive rights to its LNP technologies to Genevant for RNA applications outside of HBV, and will be entitled to a tiered royalty from Genevant on future sales of its LNP-based products.

Farris partners Hector Mackay-Dunn, Q.C., Ron Murray, and Denise Nawata advised the Special Committee of Arbutus on the transaction.

For the complete press release, click here.